You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Non-selective group I/group II metabotropic glutamate receptor antagonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 209.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.78 mL||23.9 mL||47.8 mL|
|5 mM||0.96 mL||4.78 mL||9.56 mL|
|10 mM||0.48 mL||2.39 mL||4.78 mL|
|50 mM||0.1 mL||0.48 mL||0.96 mL|
References are publications that support the biological activity of the product.
Collingridge and Watkins (1994) Phenylglycine derivatives as metabotropic glutamate receptor antagonists. TiPS 15 333 PMID: 7992387
Eaton et al (1993) Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-α-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol. 244 195 PMID: 8381746
Joly et al (1995) Molecular, functional and pharmacological characterization of the metabotropic glutamate receptor Type 5 splice variants: comparison with mGluR1. J.Neurosci. 15 3970 PMID: 7751958
If you know of a relevant reference for (RS)-MCPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (RS)-MCPG, (RS)-MCPG supplier, Non-Selective, mGlur, antagonists, Group, I, II, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, Non-selective, mGlu, 0336, Tocris Bioscience
12 Citations for (RS)-MCPG
Citations are publications that use Tocris products. Selected citations for (RS)-MCPG include:
Oh et al (2013) Synapse-specific and size-dependent mechanisms of spine structural plasticity accompanying synaptic weakening. Proc Natl Acad Sci U S A 110 E305 PMID: 23269840
Zhang and Lisman (2012) Activity-dependent regulation of synaptic strength by PSD-95 in CA1 neurons. Cereb Cortex 107 1058 PMID: 22114157
Ohba et al (2005) BDNF locally potentiates GABAergic presynaptic machineries: target-selective circuit inhibition. Proc Natl Acad Sci U S A 15 291 PMID: 15238431
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Zhuo et al (1999) On the respective roles of nitric oxide and carbon monoxide in long-term potentiation in the hippocampus. Learn Mem 5 467 PMID: 10489262
Petzold et al (2008) Coupling of neural activity to blood flow in olfactory glomeruli is mediated by astrocytic pathways. Biol Psychiatry 58 897 PMID: 18579080
Shankar et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14 837 PMID: 18568035
Tang et al (2015) Stimulation-evoked Ca2+ signals in astrocytic processes at hippocampal CA3-CA1 synapses of adult mice are modulated by glutamate and ATP. J Neurosci 35 3016 PMID: 25698739
Tronson et al (2010) Metabotropic glutamate receptor 5/Homer interactions underlie stress effects on fear. J Neurosci 68 1007 PMID: 21075228
Muddashetty et al (2007) Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 27 5338 PMID: 17507556
Jan and Westbrook (2007) Disynaptic amplification of metabotropic glutamate receptor 1 responses in the olfactory bulb. J Neurosci 27 132 PMID: 17202480
Takayasu et al (2006) Glial glutamate transporters maintain one-to-one relationship at the climbing fiber-Purkinje cell synapse by preventing glutamate spillover. J Neurophysiol 26 6563 PMID: 16775144
Do you know of a great paper that uses (RS)-MCPG from Tocris? Please let us know.
Reviews for (RS)-MCPG
Average Rating: 4 (Based on 1 Review.)
Have you used (RS)-MCPG?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
(RS)-MCPG was in use to prevent contamination of NMDA-receptor – generated response to prolonged application of glutamate with (possible) impact from metabotropic glutamate receptors (mGluRs). APV, applied after glutamate and glycine, fully suppressed NMDA-receptor response, thus suggesting no input from mGluRs (see illustration). MCPG works as expected, but takes quite a long time to dissolve for stock preparation.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.